These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors. Blum K; Chen AL; Oscar-Berman M; Chen TJ; Lubar J; White N; Lubar J; Bowirrat A; Braverman E; Schoolfield J; Waite RL; Downs BW; Madigan M; Comings DE; Davis C; Kerner MM; Knopf J; Palomo T; Giordano JJ; Morse SA; Fornari F; Barh D; Femino J; Bailey JA Int J Environ Res Public Health; 2011 Dec; 8(12):4425-59. PubMed ID: 22408582 [TBL] [Abstract][Full Text] [Related]
7. Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD). Blum K; Bowirrat A; Baron D; Lott L; Ponce JV; Brewer R; Siwicki D; Boyett B; Gondre-Lewis MC; Smith DE; Panayotis K T; Badgaiyan S; Hauser M; Fried L; A R; Downs BW; Badgaiyan RD J Syst Integr Neurosci; 2020 Aug; 6(2):. PubMed ID: 33614164 [TBL] [Abstract][Full Text] [Related]
8. Dopamine Genetics and Function in Food and Substance Abuse. Blum K; Oscar-Berman M; Barh D; Giordano J; Gold M J Genet Syndr Gene Ther; 2013 Feb; 4(121):. PubMed ID: 23543775 [TBL] [Abstract][Full Text] [Related]
9. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms. Blum K; Simpatico T; Badgaiyan RD; Demetrovics Z; Fratantonio J; Agan G; Febo M; Gold MS J Reward Defic Syndr; 2015; 1(2):75-80. PubMed ID: 27617300 [TBL] [Abstract][Full Text] [Related]
10. Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS). Blum K; Oscar-Berman M; Demetrovics Z; Barh D; Gold MS Mol Neurobiol; 2014 Dec; 50(3):765-96. PubMed ID: 24878765 [TBL] [Abstract][Full Text] [Related]
11. High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial. Moran M; Blum K; Ponce JV; Lott L; Gondré-Lewis MC; Badgaiyan S; Brewer R; Downs BW; Fynman P; Weingarten A; Cadet JL; Smith DE; Baron D; Thanos PK; Modestino EJ; Badgaiyan RD; Elman I; Gold MS Mol Neurobiol; 2021 Jul; 58(7):3335-3346. PubMed ID: 33683627 [TBL] [Abstract][Full Text] [Related]
12. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration. Blum K; Kazmi S; Modestino EJ; Downs BW; Bagchi D; Baron D; McLaughlin T; Green R; Jalali R; Thanos PK; Elman I; Badgaiyan RD; Bowirrat A; Gold MS J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33809702 [TBL] [Abstract][Full Text] [Related]
13. A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management". Blum K; Steinberg B; Gondre-Lewis MC; Baron D; Modestino EJ; Badgaiyan RD; Downs BW; Bagchi D; Brewer R; McLaughlin T; Bowirrat A; Gold M Psychol Res Behav Manag; 2021; 14():2115-2134. PubMed ID: 34949945 [TBL] [Abstract][Full Text] [Related]
14. Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) During Adolescent Brain Development. Blum K; Bowirrat A; Gondre Lewis MC; Simpatico TA; Ceccanti M; Steinberg B; Modestino EJ; Thanos PK; Baron D; McLaughlin T; Brewer R; Badgaiyan RD; Ponce JV; Lott L; Gold MS Curr Psychopharmacol; 2021 Feb; 10():. PubMed ID: 34707969 [TBL] [Abstract][Full Text] [Related]
15. Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports. Miller DK; Bowirrat A; Manka M; Miller M; Stokes S; Manka D; Allen C; Gant C; Downs BW; Smolen A; Stevens E; Yeldandi S; Blum K Postgrad Med; 2010 Nov; 122(6):188-213. PubMed ID: 21084795 [TBL] [Abstract][Full Text] [Related]
17. "TO BE OR NOT TO BE" GWAS Ends the Controversy about the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS). Blum K; Thanos PK; Hanna C; Gold MS; Baron D; Elman I Psychol Res Behav Manag; 2023; 16():4287-4291. PubMed ID: 37885829 [TBL] [Abstract][Full Text] [Related]
18. Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing. Modestino EJ; Blum K; Dennen CA; Downs BW; Bagchi D; Llanos-Gomez L; Elman I; Baron D; Thanos PK; Badgaiyan RD; Braverman ER; Gupta A; Gold MS; Bowirrat A J Pers Med; 2022 Nov; 12(12):. PubMed ID: 36556167 [TBL] [Abstract][Full Text] [Related]
19. The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS). Gilley ED; Bowirrat A; Gupta A; Giordano J; A Dennen C; R Braverman E; D Badgaiyan R; McLaughlin T; Baron D; Blum K Curr Pharm Biotechnol; 2023 Apr; ():. PubMed ID: 37102488 [TBL] [Abstract][Full Text] [Related]